Indefinite Delivery Contract HHSN261201500024I
Award Date
9/22/15
Last Date to Order
9/24/18
Federal Agency
National Cancer Institute
Awardee
IIT Research Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
The National Cancer Institute (NCI) awarded a $74,995,000 multiple-award indefinite delivery/indefinite quantity (IDIQ) contract called the PREVENT Preclinical Drug Development Program to support preclinical pharmacology, toxicology, and product development services for cancer therapy candidates. The prime contractor, IIT Research Institute (IITRI), is a non-profit division of the Illinois Institute of Technology that specializes in these preclinical services for federal agencies. Under this...
The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...
The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...
This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The contract, with a ceiling value of $0, is part of the Preclinical Agent Development Assays 2012-2016 program and supports preclinical in vitro and in vivo agent development assays. Under this IDC, IITRI provides a range of preclinical research...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $19,000,000 multiple-award IDC, designated as the "PREVENT Toxicology and Pharmacology Testing (PREVENT TOX)" program, aims to provide a structured approach to the development of cancer drugs and vaccines from...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, has been awarded an Indefinite Delivery Contract (IDC) from the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award IDC, valued at up to $149,995,000, aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical...